Dysport

Dermatologic Clinics

Volumn 22, Issue 2, 2004, Pages 213-219

  Markey, Andrew C ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b LISTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B; NEUTRALIZING ANTIBODY;

ANALGESIA; ANTIBODY PRODUCTION; BLEPHAROSPASM; CLINICAL TRIAL; CLOSTRIDIUM BOTULINUM; DETRUSOR DYSSYNERGIA; DILUTION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DYSPHONIA; DYSTONIA; ESOPHAGUS ACHALASIA; EYE DISEASE; EYELID RETRACTION; GRAVIMETRY; HEMIFACIAL SPASM; HUMAN; HYPERHIDROSIS; IMMUNOGENICITY; LARYNX DISORDER; MIGRAINE; MUSCLE CRAMP; MUSCLE DISEASE; MUSCLE WEAKNESS; NEURODERMATITIS; PRIORITY JOURNAL; REVIEW; SPASTICITY; TORTICOLLIS;

BOTULINUM TOXIN TYPE A; EUROPE; HUMANS; HYPERHIDROSIS; MUSCULAR DISEASES; NEUROMUSCULAR AGENTS; SKIN AGING;

EID: 2442600029     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00022-6     Document Type: Review

References (92)

1. Carruthers A., Carruthers J. History of the cosmetic use of Botulinum A exotoxin. Dermatol Surg. 24:1998;1168-1170
2. Markey A.C. Botulinum A exotoxin in cosmetic dermatology. Clin Exp Dermatol. 25:2000;173-175
3. Elston J.S. The clinical use of botulinum toxin. Semin Ophthalmol. 3:1988;249-260
4. Marsden C.D., Quinn N.P. The dystonias. BMJ. 300:1990;139-144
5. Kessler K.R., Skutta M., Benecke R. Long term treatment of cervial dystonia with botulinum toxin A: efficacy, safety and antibody frequency. J Neurol. 246:1999;265-274
6. Dressler D., Bigalke H. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy. Mov Disord. 17(1):2002;170-173
7. Dressler D., Munchau A., Bhatia K.P., Quinn N.P., Bigalke H. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol. 47(2):2002;118-121
8. Rollnik J.D., Matzke M., Wohlfarth K., Dengler R., Bigalke H. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study. Eur Neurol. 43(1):2000;9-12
9. Bigalke H., Wohlfarth K., Irmer A., Dengler R. Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol. 168(1):2001;162-170
10. Hambleton P., Pickett A.M. Potency equivalence of botulinum toxin preparations. J R Soc Med. 87:1994;719
11. Pickett A.M., Hambleton P. Dose standardisation of botulinum toxin. Lancet. 344:1994;474-475
12. Aoki K.R. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon. 39(12):2001;1815-1820
13. Nussgens Z., Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 235(4):1997;197-199
14. Sampaio C., Ferreira J.J., Simoes F., Rosas M.J., Magalhaes M., Correia A.P., et al. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A-Dysport and BOTOX-assuming a ratio of 4:1. Mov Disord. 12(6):1997;1013-1018
15. Lowe N.J. Botunlinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives. Dermatol Surg. 24:1998;1216-1218
16. Ranoux D., Gury C., Fondarai J., Mas J.L., Zuber M. Respective potencies of BOTOX and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 72(4):2002;459-462
17. Odergren T., Hjaltason H., Kaakkola S., Solders G., Hanko J., Fehling C., et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and BOTOX in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 64(1):1998;6-12
18. Poewe W. Respective potencies of BOTOX and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 72(4):2002;430
19. Van den Bergh P., Lison D.F. Dose standardization of Botulinum Toxin. Adv Neurol. 78:1998;231-235
20. Marion M.H., Sheehy M., Sangla S., Soulayrol S. Dose standardisation of botulinum toxin. J Neurol Neurosurg Psychiatry. 59:1995;102
21. Wohlfarth K., Goschel H., Frevert J., Dengler R., Bigalke H. Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol. 355(3):1997;335-340
22. Durif F. Clinical bioequivalence of the current commercial preparations of Botulinum toxin. Eur J Neurol. 2:1995;17-18
23. Bhaumik S., Behari M. Botulinum toxin A-injection for cervical dystonia. J Assoc Physicians India. 47(3):1999;267-270
24. Sheean G.L., Lees A.J. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A. J Neurol Neurosurg Psychiatry. 59(6):1995;601-607
25. Brans J.W., Lindeboom R., Snoek J.W., Zwarts M.J., van Weerden T.W., Brunt E.R., et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 46(4):1996;1066-1072
26. Lagueny A., Burbaud P. Mechanism of action, clinical indication and results of treatment of botulinum toxin. Neurophysiol Clin. 26(4):1996;216-226
27. Finsterer J., Fuchs I., Mamoli B. Quantitative electromyography-guided botulinum toxin treatment of cervical dystonia. Clin Neuropharmacol. 20(1):1997;42-48
28. Duran E., Chacon J.R. Spasmodic torticollis and vertebral hemangioma. Rev Neurol. 32(1):2001;60-62
29. Poewe W., Deuschl G., Nebe A., Feifel E., Wissel J., Benecke R., et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry. 64(1):1998;13-17
30. Laubis-Herrmann U., Fries K., Topka H. Low-dose botulinum toxin-a treatment of cervical dystonia - a double-blind, randomized pilot study. Eur Neurol. 47(4):2002;214-221
31. Wissel J., Kanovsky P., Ruzicka E., Bares M., Hortova H., Streitova H., et al. Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol. 248(12):2001;1073-1078
32. Jitpimolmard S., Tiamkao S., Laopaiboon M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry. 64(6):1998;751-757
33. Wissel J., Masuhr F., Schelosky L., Ebersbach G., Poewe W. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord. 12(5):1997;722-726
34. Brans J.W., de Boer I.P., Aramideh M., Ongerboer D.V., Speelman J.D. Botulinum toxin in cervical dystonia: low dosage with electromyographic guidance. J Neurol. 242(8):1995;529-534
35. Van den B.P., Francart J., Mourin S., Kollmann P., Laterre E.C. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve. 18(7):1995;720-729
36. Hesse S., Reiter F., Konrad M., Jahnke M.T. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double-blind, placebo-controlled trial. Clin Rehabil. 12(5):1998;381-388
37. Bhakta B.B., Cozens J.A., Chamberlain M.A., Bamford J.M. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry. 69(2):2000;217-221
38. Johnson C.A., Wood D.E., Swain I.D., Tromans A.M., Strike P., Burridge J.H. A pilot study to investigate the combined use of botulinum neurotoxin type A and functional electrical stimulation, with physiotherapy, in the treatment of spastic dropped foot in subacute stroke. Artif Organs. 26(3):2002;263-266
39. Bakheit A.M., Thilmann A.F., Ward A.B., Poewe W., Wissel J., Muller J., et al. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke. 31(10):2000;2402-2406
40. Bakheit A.M., Pittock S., Moore A.P., Wurker M., Otto S., Erbguth F., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol. 8(6):2001;559-565
41. van Kuijk A.A., Geurts A.C., Bevaart B.J., van Limbeek J. Treatment of upper extremity spasticity in stroke patients by focal neuronal or neuromuscular blockade: a systematic review of the literature. J Rehabil Med. 34(2):2002;51-61
42. Bhakta B.B., Cozens J.A., Bamford J.M., Chamberlain M.A. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry. 61(1):1996;30-35
43. Hesse S., Brandi-Hesse B., Bardeleben A., Werner C., Funk M. Botulinum toxin A treatment of adult upper and lower limb spasticity. Drugs Aging. 18(4):2001;255-262
44. Hesse S., Jahnke M.T., Luecke D., Mauritz K.H. Short-term electrical stimulation enhances the effectiveness of Botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett. 201(1):1995;37-40
45. Hyman N., Barnes M., Bhakta B., Cozens A., Bakheit M., Kreczy-Kleedorfer B., et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 68(6):2000;707-712
46. Heinen F., Wissel J., Philipsen A., Mall V., Leititis J.U., Schenkel A., et al. Interventional neuropediatrics: treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics. 28(6):1997;307-313
47. Deleplanque B., Lagueny A., Flurin V., Arnaud C., Pedespan J.M., Fontan D., et al. Botulinum toxin in the management of spastic hip adductors in non-ambulatory cerebral palsy children. Rev Chir Orthop Reparatrice Appar Mot. 88(3):2002;279-285
48. Ubhi T. Treatment of paediatric cerebral palsy with Dysport. Hosp Med. 61(10):2000;718-721
49. Bakheit A.M., Severa S., Cosgrove A., Morton R., Roussounis S.H., Doderlein L., et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol. 43(4):2001;234-238
50. Rasmussen L.N. Botulinum toxin. Use in the treatment of spasticity in children. Ugeskr Laeger. 162(48):2000;6557-6561
51. Desiato M.T., Risina B. The role of botulinum toxin in the neuro-rehabilitation of young patients with brachial plexus birth palsy. Pediatr Rehabil. 4(1):2001;29-36
52. Hierner R., Rollnik J.D., Berger A.C., Dengler R. Botulinum toxin type A for the treatment of biceps/triceps co-contraction in obstetrical brachial plexus lesions - preliminary results after a follow-up of 18 months. Eur J Plastic Surg. 24:2001;2-6
53. Wissel J., Kabus C., Wenzel R., Klepsch S., Schwarz U., Nebe A., et al. Botulinum toxin in writer's cramp: objective response evaluation in 31 patients. J Neurol Neurosurg Psychiatry. 61(2):1996;172-175
54. Koelman J.H., Struys M.A., Ongerboer D.V., Speelman J.D. Writer's cramp treated with botulinum injections. Ned Tijdschr Geneeskd. 142(31):1998;1768-1771
55. Cordivari C., Misra V.P., Catania S., Lees A.J. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 16(5):2001;907-913
56. Annese V., Bassotti G., Coccia G., D'onofrio V., Gatto G., Repici A., et al. Comparison of two different formulations of botulinum toxin A for the treatment of oesophageal achalasia. The Gismad Achalasia Study Group. Aliment Pharmacol Ther. 13(10):1999;1347-1350
57. Greaves R.R., Mulcahy H.E., Patchett S.E., Gorard D.A., Fairclough P.D., Alstead E.M., et al. Early experience with intrasphincteric botulinum toxin in the treatment of achalasia. Aliment Pharmacol Ther. 13(9):1999;1221-1225
58. Hep A., Dolina J., Plottova Z., Valek V., Novotny I., Kala Z. Is complex therapy of achalasia using botulinum toxin combined with balloon dilatation an effective approach? Bratisl Lek Listy. 101(8):2000;433-437
59. Hep A., Dolina J., Dite P., Plottova Z., Valek V., Kala Z., et al. Restoration of propulsive peristalsis of the esophagus in achalasia. Hepatogastroenterology. 47(35):2000;1203-1204
60. Zielinska M., Selmaj K. A case of laryngeal adductor dystonia treated with transcutaneous injections of botulinum toxin. Neurol Neurochir Pol. 32(5):1998;1273-1280
61. Galardi G., Guerriero R., Amadio S., Leocani L., Teggi R., Melloni G., et al. Sporadic failure of botulinum toxin treatment in usually responsive patients with adductor spasmodic dysphonia. Neurol Sci. 22(4):2001;303-306
62. Schneider I., Thumfart W.F., Pototschnig C., Eckel H.E. Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol. 103(1):1994;31-35
63. Pototschnig C.A., Schneider I., Eckel H.E., Thumfart W.F. Repeatedly successful closure of the larynx for the treatment of chronic aspiration with the use of botulinum toxin A. Ann Otol Rhinol Laryngol. 105(7):1996;521-524
64. Petit H., Wiart L., Gaujard E., Le Breton F., Ferriere J.M., Lagueny A., et al. Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord. 36(2):1998;91-94
65. Schurch B., Schmid D.M., Knapp P.A. An update on the treatment of detrusor-sphincter dyssynergia with botulinum toxin type A. Eur J Neurol. 6:1999;S83-S89
66. Schulte-Mattler W.J., Wieser T., Zierz S. Treatment of tension-type headache with botulinum toxin: a pilot study. Eur J Med Res. 4(5):1999;183-186
67. Rollnik J.D., Dengler R. Botulinum toxin (Dysport) in tension-type headaches. Acta Neurochir Suppl. 79:2002;123-126
68. Bushara K.O., Park D.M., Jones J.C., Schutta H.S. Botulinum toxin-a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol. 21(4):1996;276-278
69. Schnider P., Binder M., Auff E., Kittler H., Berger T., Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol. 136(4):1997;548-552
70. Heckmann M., Breit S., Ceballos-Baumann A., Schaller M., Plewig G. Axillary hyperhidrosis: successful treatment with botulinum toxin A. Hautarzt. 49(2):1998;101-103
71. Heckmann M., Breit S., Ceballos-Baumann A., Schaller G., Plewig G. Side-controlled intradermal injection of botulinum toxin A in recalcitrant axillary hyperhidrosis. J Am Acad Dermatol. 41(6):1999;987-990
72. Heckmann M. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med. 344:2001;488-493
73. Schnider P., Binder M., Kittler H., Birner P., Starkel D., Wolff K., et al. A randomized, double-blind, placebo-controlled trial of botulinum A toxin for severe axillary hyperhidrosis. Br J Dermatol. 140(4):1999;677-680
74. Schnider P., Moraru E., Kittler H., Binder M., Kranz G., Voller B., et al. Treatment of focal hyperhidrosis with botulinum toxin type A: long-term follow-up in 61 patients. Br J Dermatol. 145(2):2001;289-293
75. Whatling P., Collin J. Botulinum toxin injection is an effective treatment for axillary hyperhidrosis. Br J Surg. 88:2001;814-815
76. Filosto M., Bertolasi L., Fincati E., Priori A., Tomelleri G., Chieregato G., et al. Axillary injection of botulinum A toxin in a patient with muscle cramps associated with severe axillary hyperhidrosis. Acta Neurol Belg. 101(2):2001;121-123
77. Boger A., Herath H., Rompel R., Ferbert A. Botulinum toxin for treatment of craniofacial hyperhidrosis. J Neurol. 247(11):2000;857-861
78. Braune C., Erbguth F., Birklein F. Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometry. Br J Dermatol. 144(1):2001;111-117
79. Moraru E., Voller B., Auff E., Schnider P. Dose thresholds and local anhidrotic effect of botulinum A toxin injections (Dysport). Br J Dermatol. 145(2):2001;368
80. von Lindern J.J., Niederhagen B., Appel T., Berge S., Reich R.H. New prospects in the treatment of traumatic and postoperative parotid fistulas with type A botulinum toxin. Plast Reconstr Surg. 109:2002;2443-2445
81. Keegan D.J., Geerling G., Lee J.P., Blake G., Collin J.R., Plant G.T. Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation. Br J Ophthalmol. 86(1):2002;43-46
82. Olver J.M. Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease. Br J Ophthalmol. 82(5):1998;528-533
83. Heckmann M., Heyer G., Brunner B., Plewig G. Botulinum toxin type A injection in the treatment of lichen simplex: an open pilot study. J Am Acad Dermatol. 46(4):2002;617-619
84. Chalkiadaki A., Rohr U.P., Hefter H. Early pain reduction in the treatment of spasticity after a single injection of botulinum A toxin. Dtsch Med Wochenschr. 126(48):2001;1361-1364
85. Carruthers A., Carruthers J. The treatment of glabellar furrows with botulinum A exotoxin. J Dermatol Surg Oncol. 16:1990;83
86. Carruthers A., Carruthers J. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 18:1992;17-21
87. Ascher B., Klap P., Marion M.H., et al. La toxine botulique dans le treatment de rides fronto-glabellaires et de la region orbitaire. Ann Chir Plast Esthet. 40:1995;67-76
88. Le Louarn C. Toxine botulique et rides faciales: une nouvelle procedure d'injection. Ann Chir Plast Esthet. 43:1998;526-533
89. Le Louarn C. Botulinum toxin A and facial lines: the variable concentration. Aesth Plast Surg. 25:2001;73-84
90. Erian A., Ionescu N.E. Combination treatment of glabellar rhytids. Int J Cosmetic Surg. 7:1999;14-17
91. Feller G., Bayerl C., Jung E.G., Rzany B. Treatment of dynamic facial wrinkles with Botulinum toxin type A (Dysport). Aktuelle Dermatologie. 26:2000;65-69
92. Heckmann M., Schon-Hupka G. Quantification of the efficacy of botulinum toxin type A by digital image analysis. J Am Acad Dermatol. 45:2001;508-514